<?xml version='1.0' encoding='utf-8'?>
<document id="9591934"><sentence text="Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling."><entity charOffset="57-71" id="DDI-PubMed.9591934.s1.e0" text="phenobarbitone" /></sentence><sentence text="Nonlinear mixed-effects modeling (NONMEM) was used to estimate the effects of drug drug interaction on phenobarbitone clearance values, using 648 serum levels gathered during the routine clinical care of 349 pediatric and adult epileptic patients (age range, 0"><entity charOffset="103-117" id="DDI-PubMed.9591934.s2.e0" text="phenobarbitone" /></sentence><sentence text="4-33" /><sentence text="3 years)" /><sentence text=" Patients received phenobarbitone as monotherapy or in combination with either of the antiepileptic drugs carbamazepine or valproic acid"><entity charOffset="19-33" id="DDI-PubMed.9591934.s5.e0" text="phenobarbitone" /><entity charOffset="106-119" id="DDI-PubMed.9591934.s5.e1" text="carbamazepine" /><entity charOffset="123-136" id="DDI-PubMed.9591934.s5.e2" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.9591934.s5.e0" e2="DDI-PubMed.9591934.s5.e0" /><pair ddi="false" e1="DDI-PubMed.9591934.s5.e0" e2="DDI-PubMed.9591934.s5.e1" /><pair ddi="false" e1="DDI-PubMed.9591934.s5.e0" e2="DDI-PubMed.9591934.s5.e2" /><pair ddi="false" e1="DDI-PubMed.9591934.s5.e1" e2="DDI-PubMed.9591934.s5.e1" /><pair ddi="false" e1="DDI-PubMed.9591934.s5.e1" e2="DDI-PubMed.9591934.s5.e2" /></sentence><sentence text="" /><sentence text="The final model describing phenobarbitone clearance was CL = 52"><entity charOffset="27-41" id="DDI-PubMed.9591934.s7.e0" text="phenobarbitone" /></sentence><sentence text="3 x TBW(-0" /><sentence text="567) x CO, where CL is clearance (ml x kg(-1) x h(-1)), TBW is total body weight (kg) and CO is a scaling factor for concomitant medication with a value of 1 for patients on phenobarbitone monotherapy, 46"><entity charOffset="90-92" id="DDI-PubMed.9591934.s9.e0" text="CO" /><entity charOffset="174-188" id="DDI-PubMed.9591934.s9.e1" text="phenobarbitone" /><entity charOffset="7-20" id="DDI-PubMed.9591934.s9.e2" text="CO" /><pair ddi="false" e1="DDI-PubMed.9591934.s9.e2" e2="DDI-PubMed.9591934.s9.e2" /><pair ddi="false" e1="DDI-PubMed.9591934.s9.e2" e2="DDI-PubMed.9591934.s9.e0" /><pair ddi="false" e1="DDI-PubMed.9591934.s9.e2" e2="DDI-PubMed.9591934.s9.e1" /><pair ddi="false" e1="DDI-PubMed.9591934.s9.e0" e2="DDI-PubMed.9591934.s9.e0" /><pair ddi="false" e1="DDI-PubMed.9591934.s9.e0" e2="DDI-PubMed.9591934.s9.e1" /></sentence><sentence text="4(-1/TBW) for those patients receiving concomitant carbamazepine and 0"><entity charOffset="51-64" id="DDI-PubMed.9591934.s10.e0" text="carbamazepine" /></sentence><sentence text="642 for those patients receiving concomitant valproic acid"><entity charOffset="45-58" id="DDI-PubMed.9591934.s11.e0" text="valproic acid" /></sentence><sentence text=" Phenobarbitone CL was highest in the very young and decreased in a weight-related fashion in children, with minimal changes observed in adults" /><sentence text=" This pattern was consistent whether phenobarbitone was administered alone or coadministered with carbamazepine or valproic acid"><entity charOffset="37-51" id="DDI-PubMed.9591934.s13.e0" text="phenobarbitone" /><entity charOffset="98-111" id="DDI-PubMed.9591934.s13.e1" text="carbamazepine" /><entity charOffset="115-128" id="DDI-PubMed.9591934.s13.e2" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.9591934.s13.e0" e2="DDI-PubMed.9591934.s13.e0" /><pair ddi="false" e1="DDI-PubMed.9591934.s13.e0" e2="DDI-PubMed.9591934.s13.e1" /><pair ddi="false" e1="DDI-PubMed.9591934.s13.e0" e2="DDI-PubMed.9591934.s13.e2" /><pair ddi="false" e1="DDI-PubMed.9591934.s13.e1" e2="DDI-PubMed.9591934.s13.e1" /><pair ddi="false" e1="DDI-PubMed.9591934.s13.e1" e2="DDI-PubMed.9591934.s13.e2" /></sentence><sentence text=" When phenobarbitone was coadministered with carbamazepine or valproic acid, phenobarbitone CL decreased compared with that in monotherapy"><entity charOffset="6-20" id="DDI-PubMed.9591934.s14.e0" text="phenobarbitone" /><entity charOffset="45-58" id="DDI-PubMed.9591934.s14.e1" text="carbamazepine" /><entity charOffset="62-75" id="DDI-PubMed.9591934.s14.e2" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.9591934.s14.e0" e2="DDI-PubMed.9591934.s14.e0" /><pair ddi="false" e1="DDI-PubMed.9591934.s14.e0" e2="DDI-PubMed.9591934.s14.e1" /><pair ddi="false" e1="DDI-PubMed.9591934.s14.e0" e2="DDI-PubMed.9591934.s14.e2" /><pair ddi="false" e1="DDI-PubMed.9591934.s14.e1" e2="DDI-PubMed.9591934.s14.e1" /><pair ddi="false" e1="DDI-PubMed.9591934.s14.e1" e2="DDI-PubMed.9591934.s14.e2" /></sentence><sentence text=" Its magnitudes in the presence of carbamazepine are maximal in early childhood (about 54%) and decreased in a weight-related fashion in older children, with minimal changes observed in adults"><entity charOffset="35-48" id="DDI-PubMed.9591934.s15.e0" text="carbamazepine" /></sentence><sentence text=" Concomitant administration of phenobarbitone and valproic acid resulted in a 35"><entity charOffset="31-45" id="DDI-PubMed.9591934.s16.e0" text="phenobarbitone" /><entity charOffset="50-63" id="DDI-PubMed.9591934.s16.e1" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.9591934.s16.e0" e2="DDI-PubMed.9591934.s16.e0" /><pair ddi="false" e1="DDI-PubMed.9591934.s16.e0" e2="DDI-PubMed.9591934.s16.e1" /></sentence><sentence text="8% decrease of phenobarbitone CL" /><sentence text="" /></document>